Licenses upon Termination. (a) Upon any termination of this Agreement, Alnylam shall enter into an agreement containing substantially the same provisions as this Agreement with any Sublicensees of Tekmira existing at the time of such termination, covering the Tekmira Products that had been licensed to such Sublicensee by Tekmira in compliance with this Agreement, provided that at the time of any termination of this Agreement, such Sublicensees are in full compliance with the terms and conditions of the sublicense agreement. Alnylam acknowledges that such Sublicensees of Tekmira that are then in full compliance with the terms and conditions of their respective sublicense agreement are third party beneficiaries of this Agreement, including this Section 9.6(a).
Licenses upon Termination. Where this Agreement is terminated pursuant to Section 8.1, each Party's intellectual property rights shall revert to such Party and the Parties shall execute cross-licensing agreements for any Joint Patent Rights or Joint Technology arising from this Agreement. The Parties shall immediately following the delivery of a notice pursuant to Section 8.1, negotiate in good faith such cross-licensing agreements. If the Parties fail to negotiate and sign cross-licensing agreements before the expiration of a period of one hundred and eighty (180) days following delivery of the notice pursuant to Section 8.1, either Party (the "Electing Party") may, by written notice (the "Notice") accompanied by a Submitted License (as defined hereinafter) at its option offer to the other Party: (i) to have an exclusive worldwide license for the Joint Patent Rights or Joint Technology, the whole in accordance with the terms and conditions of an agreement to be submitted by the Electing Party to the other Party (the "Submitted License"); or (ii) to grant to the other Party (the "Non-Electing Party") an exclusive worldwide license for the Joint Patent Rights or Joint Technology in accordance with the Submitted License. The Non-Electing Party shall have the option to either (i) grant to the Electing Party a worldwide exclusive license for the Joint Patent Rights or Joint Technology in accordance with the terms and conditions of the Submitted License, or (ii) to have an exclusive worldwide license for Joint Patent Rights or Joint Technology in accordance with the terms of the Submitted License. Such election may be made by the Non-Electing Party in writing, addressed to the Electing Party (the "Election Notice") within ninety (90) days following receipt of the Notice, failing which he shall be deemed to have elected to grant the Electing Party a license upon the term of the Submitted License. The Parties shall execute a license based on the Submitted License within six (6) months following receipt by the Electing Party of the Election Notice.
Licenses upon Termination. (a) Upon termination of this Agreement by OpticNet pursuant to Section 10.2(a) above OpticNet shall have the right, without payment of royalties to
Licenses upon Termination. 22 9.2 Termination upon the Occurrence of an Event of Termination .............. 23 9.3 Survival of Obligations; Return of Confidential Information ............. 24 ARTICLE 10 REPRESENTATIONS AND WARRANTIES 24 ARTICLE 11 COVENANTS 25 11.1 Affirmative Covenants Other than Reporting Requirements 25 ARTICLE 12 DISPUTE RESOLUTION 25 ARTICLE 13 NOTICES 26 ARTICLE 14 MISCELLANEOUS 26
Licenses upon Termination. Before the expiration of a period of one hundred and twenty (120) days following delivery of a notice pursuant to Section 8.1, either Party (the "ELECTING PARTY") may, by written notice (the "NOTICE") accompanied by a Submitted License (as defined hereinafter) at its option offer to the other Party: (a) to have an exclusive worldwide license for any or all of the Joint Patent Rights or Joint Technology in accordance with the terms and conditions of an agreement to be submitted by the Electing Party to the other Party (the "SUBMITTED LICENSE"); or (b) to grant to the other Party (the "NON-ELECTING PARTY") an exclusive worldwide license for such Joint Patent Rights or Joint Technology in accordance with the Submitted License. The Non-Electing Party shall have the option to either (i) grant to the Electing Party a worldwide exclusive license for such Joint Patent Rights or Joint Technology in accordance with the terms and conditions of the Submitted License, or (ii) to have an exclusive worldwide license for such Joint Patent Rights or Joint Technology in accordance with the terms of the Submitted License.
Licenses upon Termination. CANbridge hereby grants to PUMA:
Licenses upon Termination. Upon termination of this Agreement pursuant to Section 7.1, Helicon shall grant CSHL a perpetual, worldwide, royalty-free, non-exclusive license under Helicon's rights in the Joint Technology for research purposes only.
Licenses upon Termination. If INCY elects to supply to Zai Lab such Licensed Product after the expiration of the Royalty Term in accordance with clause (a) of this Section 9.1.3, such supply of Licensed Product(s) by or on behalf of INCY to Zai Lab will be exclusive on a Region-by-Region basis for Licensed Products in the Field during such time, if any, as the Commercialization portion of the Surviving License for such Licensed Product(s) in such Region is exclusive in accordance with clause (c) of Section 9.3.1 (Licenses Upon Termination).
Licenses upon Termination. (a) Upon the expiration of a Royalty Term with respect to a Licensed Product in a Region(s), all licenses granted by INCY to Zai Lab for such Licensed Product in such Region(s) for which Zai Lab has paid all royalties and milestone payments due under this Agreement will be deemed fully paid up and irrevocable, but on a non-exclusive basis, except as provided under clauses (b) and (c) of this Section 9.3.1 (each a “Surviving License”).
Licenses upon Termination. Upon any termination of this Agreement pursuant to Section 12.3 (Early Termination), CANbridge will grant, and hereby does grant to PUMA: (a) a non-exclusive, fully paid-up, royalty-free, worldwide, transferable, perpetual and irrevocable license, with the right to sublicense, under all intellectual property rights Controlled [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Confidential Treatment Requested by Puma Biotechnology, Inc. EXECUTION COPY by CANbridge claiming Inventions that are necessary or reasonably useful to make, use, sell, offer for sale, or import the Licensed Products as they exist at the time of such termination of this Agreement to make, use, sell, offer for sale, or import the Licensed Products and (b) a fully paid- up, royalty-free, worldwide, transferable, sublicensable, perpetual and irrevocable license to use Trademarks specifically identifying the Licensed Products, excluding for clarity all Trademarks also used in connection with CANbridge’s business other than with respect to Licensed Product, for the purpose of manufacturing, marketing, distributing, selling, and otherwise Developing and Commercializing, such Licensed Product.
